@Article{,
AUTHOR = {Mihir Desai, Mo Bidair, Naeem Bhojani, Andrew Trainer, Andrew Arther, Eugene Kramolowsky, Leo Doumanian, Dean Elterman, Ronald P. Kaufman, Jr., James Lingeman, Amy Krambeck, Gregg Eure, Gopal Badlani, Mark Plante, Edward Uchio, Greg Gin, Larry Goldenberg, Ryan Paterson, Alan So, Mitchell R. Humphreys, Claus G. Roehrborn, Steven Kaplan, Jay Motola, Kevin C. Zorn},
TITLE = {Aquablation for benign prostatic hyperplasia in large prostates (80-150 cc): 2-year results},
JOURNAL = {Canadian Journal of Urology},
VOLUME = {27},
YEAR = {2020},
NUMBER = {2},
PAGES = {10147--10153},
URL = {http://www.techscience.com/CJU/v27n2/60407},
ISSN = {1488-5581},
ABSTRACT = {<b>Introduction:</b> To report 2-year safety and effectiveness of the Aquablation procedure for the treatment of men with symptomatic benign prostatic hyperplasia (BPH) and large-volume 80-150 cc prostates.<br/>
<b>Materials and methods:</b> Between September-December 2017, 101 men with moderate-to-severe BPH symptoms and prostate volumes of 80-150 cc underwent an ultrasound-guided robotically executed Aquablation procedure in a prospective multicenter international clinical trial (WATER II). Baseline, procedural and follow-up parameters were recorded at baseline and scheduled postoperative visits. Herein we report 2-year safety and efficacy for this cohort.<br/>
<b>Results:</b> Mean prostate volume was 107 cc (range 80-150 cc). Mean IPSS improved from 23.2 at baseline to 5.8 at 2 years (17-point improvement, p < .0001). Mean IPSS quality of life improved from 4.6 at baseline to 1.1 at 2 years (p < .0001). Maximum urinary flow increased from 8.7 to 18.2 cc/sec. Two subjects underwent a repeat procedure for BPH symptoms over the 2-year follow-up period. By 2 years or study exit, all but 2 of 74 subjects stopped taking alpha blockers. Similarly, all but 4 of 32 subjects stopped taking 5α-reductase inhibitors.<br/>
<b>Conclusions:</b> Two-year prospective multicenter follow-up demonstrated that the Aquablation procedure is safe and effective in the treatment of men with LUTS due to BPH and prostates 80-150 cc with durable treatment efficacy, acceptable safety profile, and a low retreatment rate. ClinicalTrials.gov number, NCT03123250.},
DOI = {}
}